Inventor
GILL SAAR
US31 patents
⚠️ This page may combine multiple inventors who share the name “GILL SAAR”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV PENNSYLVANIA
19 patentsUS11034749B2Jun 15, 2021
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA10 citations93
US10548922B2Feb 4, 2020
Methods and compositions for gene editing in hematopoietic stem cells
UNIV PENNSYLVANIA17 citations89
US11191784B2Dec 7, 2021
Methods and composition for gene delivery using an engineered viral particle
UNIV PENNSYLVANIA4 citations84
US10357514B2Jul 23, 2019
Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
UNIV PENNSYLVANIA18 citations82
US12163119B2Dec 10, 2024
Methods and composition for gene delivery using an engineered viral particle
UNIV PENNSYLVANIA1 citations73
US11306133B2Apr 19, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA1 citations72
US11673964B2Jun 13, 2023
Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
UNIV PENNSYLVANIA2 citations71
US11747346B2Sep 5, 2023
Biomarkers predictive of cytokine release syndrome
UNIV PENNSYLVANIA3 citations62
US11723927B2Aug 15, 2023
Methods and composition for gene delivery using an engineered viral particle
UNIV PENNSYLVANIA0 citations62
US11498954B2Nov 15, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US11407805B2Aug 9, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US11359002B2Jun 14, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US11332511B2May 17, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US11325963B2May 10, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US11319358B2May 3, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US11306134B2Apr 19, 2022
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
UNIV PENNSYLVANIA0 citations62
US12227588B2Feb 18, 2025
Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
UNIV PENNSYLVANIA0 citations61
US11771719B2Oct 3, 2023
Methods and compositions for gene editing in hematopoietic stem cells
UNIV PENNSYLVANIA0 citations58
US11884716B2Jan 30, 2024
Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells
UNIV PENNSYLVANIA0 citations52
NOVARTIS AG
10 patentsUS10253086B2Apr 9, 2019
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG37 citations93
US11149076B2Oct 19, 2021
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG9 citations84
US11026976B2Jun 8, 2021
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG6 citations82
US12344657B2Jul 1, 2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG1 citations73
US11028177B2Jun 8, 2021
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
NOVARTIS AG4 citations73
US11872249B2Jan 16, 2024
Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
NOVARTIS AG2 citations71
US10568947B2Feb 25, 2020
Treatment of cancer using a CLL-1 chimeric antigen receptor
NOVARTIS AG6 citations71
US11591404B2Feb 28, 2023
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG1 citations62
USRE49847EFeb 27, 2024
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG0 citations61